Skip to main content
ZNTL logo

Zentalis Pharmaceuticals, Inc.

ZNTLNASDAQHealthcareBiotechnology

$1.98Today:- (-)1Y +46.95%

As of Oct 27, 2026 close

Market cap
$141.23M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.21$6.95
Volume (live)
-
Avg. volume (3M)
1.36M

Zentalis Pharmaceuticals (ZNTL) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Zentalis Pharmaceuticals used $125.25M of cash in operating activities. Free cash flow was −$125.25M. It repurchased $9.98M of its own shares.

Zentalis Pharmaceuticals Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Zentalis Pharmaceuticals, Inc. (ZNTL) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-137.06-165.87-292.19-237.11-166.09-118.55-46.38-23.43
Depreciation & Amortization0.741.291.391.430.540.160.110.05
Deferred Income Tax0.000.00-0.85-0.77-2.510.020.002.37
Stock Based Compensation20.7267.2754.8246.8435.7423.150.620.31
Change in Working Capital-9.12-16.545.8613.2516.617.846.51-1.18
Change in Accounts Receivable5.00-5.000.000.000.41-0.280.78-0.25
Change in Inventory0.000.000.000.000.00-5.520.00-1.86
Change in Accounts Payable-17.32-18.0210.9215.5313.9614.317.120.98
Change in Other Working Capital3.19-47.4315.05-2.282.64-0.67-1.39-0.04
Other Operating Activities-0.53-47.4315.0512.61-40.890.560.00-2.37
Net Cash from Operating Activities-125.25-170.86-207.82-163.75-154.09-86.83-39.14-24.25
Investing Activities
Capital Expenditures0.00-0.22-0.58-2.55-6.11-0.76-0.35-0.23
Acquisitions0.000.070.000.11-14.3218.420.000.00
Purchases of Investments-139.49-127.96-549.18-533.16-363.51-400.980.000.00
Sales/Maturities of Investments270.41304.68505.31421.53365.82116.910.000.00
Other Investing Activities0.700.000.00-0.11-14.32-18.420.000.00
Net Cash from Investing Activities131.62176.56-44.46-114.18-18.12-284.83-0.35-0.23
Financing Activities
Common Stock Issued5.690.35237.30261.04179.67327.790.000.02
Common Stock Repurchased-9.98-0.240.000.00-1.150.000.000.00
Other Financing Activities0.00-0.240.000.00-1.1532.6581.839.46
Net Cash from Financing Activities-4.280.11237.30261.04178.52360.4481.839.47
Summary
Net Change in Cash2.095.81-14.98-16.896.31-11.2242.34-15.01
Cash at Beginning of Period36.5330.7245.7062.5856.2767.4925.1540.16
Cash at End of Period38.6236.5330.7245.7062.5856.2767.4925.15
Free Cash Flow-125.25-171.08-208.41-166.30-160.20-87.58-39.50-24.48
Supplemental Disclosures
Income Taxes Paid-0.360.140.010.020.02--

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Zentalis Pharmaceuticals Cash Flow

What is Zentalis Pharmaceuticals's free cash flow?

Zentalis Pharmaceuticals had negative free cash flow of $125.25M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Zentalis Pharmaceuticals pay dividends or buy back shares?

Yes. In fiscal 2025 Zentalis Pharmaceuticals returned $9.98M in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition